Persica Pharmaceuticals Ltd
- Biotech or pharma, therapeutic R&D
Persica has developed PP353, a paradigm-shifting treatment for chronic Low Back Pain (cLBP). PP353 is a non-opioid, one-off treatment which addresses an underlying cause, rather than just symptoms. PP353 has just completed a Ph1(b) study, the Modic Trial, with compelling results; meeting the primary endpoint : statistically significant, clinically meaningful and durable reduction in pain and disability Reductions in pain seen from 3 months up to at least 12 months.
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}